title: [PET with amyloid ligands should not be applied routinely in early diagnostics of Alzheimer's disease].
abstract: Recent diagnostic criteria for Alzheimer's disease incorporate biomarkers in order to increase the diagnostic accuracy. In a recent Cochrane review the ligand (11)C-PiB showed a high sensitivity, but low specificity for detecting patients with mild cognitive impairment who would develop Alzheimer's dementia. Given the evolution of Alzheimer pathology, these findings are not surprising. With current limited treatment options for MCI, (11)C-PiB-PET cannot be recommended for routine use in MCI and should be used only in selected cases where a positive scan will alter management.
authors: Nationalt Videnscenter for Demens, Neurologisk Afdeling, Neurocentret, Rigshospitalet, Blegdamsvej 9, 2100 København Ø. steen.gregers.hasselbalch@regionh.dk.
authors: Steen Gregers
authors: SG
authors: Hasselbalch
mesh_terms: D000544:Alzheimer Disease / Q000000981:diagnostic imaging*; D000814:Aniline Compounds; D052160:Benzothiazoles; D042241:Early Diagnosis; D006801:Humans; D049268:Positron-Emission Tomography / Q000379:methods*; D012196:Review Literature as Topic; D012680:Sensitivity and Specificity; D013844:Thiazoles
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D000814:Aniline Compounds; D052160:Benzothiazoles; D013844:Thiazoles